patent.fyi
Applications  /  US 2026/0355209
United States Patent Application Publication

US 2026/0355209 A1

Published
Nov 12, 2026
Filed
May 8, 2026
Earliest date on the face
May 9, 2025
Classification
A61K 31/5377
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Calcineurin inhibitor infusion

What ifWhat if intravenous tacrolimus supplied the immunosuppressive activity?
Claim language“mycophenolate or a pharmaceutically acceptable salt or free acid thereof”

A nonionic surfactant and ethanol keep tacrolimus dissolved in an infusion concentrate. The concentrate is diluted in an aqueous infusion fluid before administration, and tacrolimus suppresses T-cell activation by inhibiting calcineurin.

1.2Unbuffered ph control at filling

What ifWhat if a one-time acid adjustment and a sealed container controlled pH?
Claim language“a buffering system maintaining pH”

Hydrochloric acid sets the initial pH of the bulk solution before sterile filtration and filling. A sealed glass ampoule limits exchange with ambient gases, and stability testing measures pH drift and hydrolysis during storage.

1.4Oil vehicle for injection

What ifWhat if a sterile oil carried the active ingredient in an intramuscular suspension?
Claim language“an aqueous vehicle”

Micronized crystals of the active ingredient are dispersed in sterile medium-chain triglyceride oil and aseptically filled. The vial is shaken to redistribute the particles before withdrawal, and the particles dissolve as they contact tissue fluid after injection.

1.5Freeze-dried vial for reconstitution

What ifWhat if the vial held a sterile freeze-dried cake that was dissolved before infusion?
Claim language“a sterile solution suitable for direct administration without reconstitution”

An aqueous drug solution is sterile-filtered into vials, frozen, and dried under vacuum to reduce residual moisture and limit hydrolysis during storage. Water for injection dissolves the cake, and the resulting solution is diluted to the infusion concentration.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Single dose vials for veterinary hospitals

A veterinary hospital pharmacy stocks sterile aqueous mycophenolate solution in single-dose vials of one labeled concentration. Each vial contains the active ingredient, a pH buffer, and a tonicity agent dissolved in water for injection. Pharmacy staff use the prescribed dose and labeled concentration to calculate the withdrawal volume and transfer that volume into a sterile administration syringe without reconstitution.

Component substitution

Acetate buffer for acidic ph control

Acetic acid and sodium acetate replace the citrate buffering system in the aqueous mycophenolate formulation. The acid-to-salt ratio sets the target pH, and the total acetate concentration sets the buffer capacity. The acetate contribution to osmolality is included when setting the tonicity agent concentration, and sealed vials are assayed for pH, dissolved drug, and related substances during storage at 25 °C.

Glycerol as the tonicity agent

Glycerol replaces sodium chloride, dextrose, or mannitol as the tonicity agent in the buffered mycophenolate solution. The active ingredient and buffer are dissolved in a portion of the water for injection, and glycerol is added before the batch is brought to final volume. A freezing-point osmometer measures the finished solution, and the glycerol concentration is set during development to bring measured osmolality into the specified range.

Parameter or scale variation

Two fill volumes at one concentration

A single batch of buffered, tonicity-adjusted aqueous mycophenolate solution supplies 2 mL and 5 mL fills at the same active concentration. A programmable filling pump dispenses each volume into a corresponding sterile vial, and a balance checks fill mass against the target volume multiplied by the measured solution density. Separate vial sets from each fill are stored at 25 °C and sampled at 0, 1, 3, and 6 months for pH, potency, and related substances.

Combination with existing systems

Prefilled syringe for programmable pump delivery

The sterile aqueous mycophenolate solution, buffer, and tonicity agent are packaged in a prefilled syringe with a barrel geometry supported by a programmable syringe pump. The syringe flange seats in the pump holder, the drive engages the plunger, and the syringe outlet connects to a sterile infusion line. The pump uses the selected syringe profile to convert the programmed volumetric rate into plunger travel.

Automated or data-driven variant

Automated tracking of storage impurities

Sealed vials of the finished aqueous mycophenolate solution are stored at 25 °C and assigned identifiers that encode the batch and sampling time. At each scheduled pull, a liquid chromatography autosampler draws from prepared samples, and software calculates concentrations of mycophenolate mofetil and mycophenolic acid from separate calibration curves. The software links results to the vial identifiers and flags individual or total related-substance results that exceed predefined limits.

Specific version of a part

Tonicity set during infusion preparation

The concentrate contains the active ingredient and the excipients required for solubility and pH control. A measured volume is transferred into a larger volume of isotonic infusion fluid, with the dilution ratio set using the measured osmolality of the admixture.

Mycophenolate mofetil hydrochloride

Mycophenolate mofetil hydrochloride supplies the active ingredient as a protonated ester prodrug. Esterases convert the prodrug to mycophenolic acid after administration.

Citrate buffer at acidic ph

Citric acid and sodium citrate form a buffer set to pH 4.0. Their ratio sets the pH, and their combined concentration determines the buffer capacity.

Sterile solution in sealed ampoules

The finished solution passes through a sterilizing-grade 0.22 µm membrane and is aseptically filled into glass ampoules for direct administration. A stability-indicating liquid chromatography assay tracks mycophenolic acid and other degradation products in sealed ampoules stored at 25 °C.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2008/0280977 A1
Published
Nov 13, 2008
Filed
Jul 18, 2008
Class
A61K 31/343
Document BUS 2012/0237601 A1
Published
Sep 20, 2012
Filed
May 29, 2012
Class
A61K 9/28
Claim 1
Document A
Document B
1.1(a) mycophenolate or a pharmaceutically acceptable salt or free acid thereof;
Pharmaceutical formulations of the invention contain mycophenolic acid ester, and preferably the mofetil ester. Also included are pharmaceutically acceptable salts of the mofetil ester such as, for example, acetic, benzoic, fumaric, maleic, citric, tartaric, gentisic, methane-sulfonic, ethanesulfonic, benzenesulfonic and laurylsulfonic, taurocholat, hydrobromide, or hydrochloride salts.
A · US 2008/0280977 A1 · ¶ 56
When mycophenolate salt is used, cationic salts of MPA, e.g. alkali metal salts, especially the sodium salt, alkaline earth metal salts, an ammonium salt or a salt with an organic base may be used. According to the present invention, preferably the mono-sodium salt may be used.
B · US 2012/0237601 A1 · ¶ 16
1.2(b) a buffering system maintaining pH;
More specifically, the term “enteric coating”, as used herein, refers to a coating which remains intact for at least 2 hours, in contact with artificial gastric juices such as HCl of pH-1 at 36 to 38° C. and preferably thereafter disintegrates within 30 minutes in artificial intestinal juices such as a KH2PO4 buffered solution of pH 6.8.
B · US 2012/0237601 A1 · ¶ 40
1.3(c) a tonicity adjusting agent; and
Sweetening agents such as sorbitol, saccharin, sodium saccharin, sucrose, aspartame, fructose, mannitol and invert sugar may be added to improve the taste.
A · US 2008/0280977 A1 · ¶ 68
1.4(d) an aqueous vehicle;
Enteric coating material, e.g. polymethacrylates such as disclosed above or other acidic coating materials may also be applied from an aqueous medium. If desired for cellulose phthalates and other acidic coating materials, a water soluble salt, e.g. an ammonium salt, may be formed and an aqueous solution thereof may be used.
B · US 2012/0237601 A1 · ¶ 53
1.5wherein the composition is present as a sterile solution suitable for direct administration without reconstitution and exhibits controlled impurity formation during storage at 25 °C.

An empty cell means only that no passage was reproduced there.

Statements in these documents
When converting MPA to mycophenolate mofetil according to the process disclosed in WO 00/34503, it was observed that a large part of the MPA is left unconverted, and impurities are formed.
A · US 2008/0280977 A1 · ¶ 8
Difficulties in the formulation of oral solid dosage forms, e.g. tablets, comprising mycophenolic acid or mycophenolate salt, can be for example the low bulk density of the drug substance, resulting in e.g. low mechanical stability of the solid dosage form and/or unfavourable size particularly when a high amount of excipients or additives is added to improve the mechanical stability properties.
B · US 2012/0237601 A1 · ¶ 5
It has now been found that pharmaceutically acceptable oral solid dosage forms, e.g. in the form of tablets, of mycophenolic acid or mycophenolate salt are obtainable in a favourable small and mechanically stable form with a high drug loading.
B · US 2012/0237601 A1 · ¶ 6
Cite aspatent.fyi, US 2026/0355209 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355209/, SHA-256 268a36c4c71b5a01db1de4e4b4a9dfb7c97ef82131609d7234f6c84379833948
First published
Permanent addresshttps://patent.fyi/US20260355209/
Content fingerprint (SHA-256)268a36c4c71b5a01db1de4e4b4a9dfb7c97ef82131609d7234f6c84379833948
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi